EGFR突变患者TKI治疗与化疗联用解说.pptxVIP

EGFR突变患者TKI治疗与化疗同时进行的疗效评价;内容;同步联用Concurrent Combination;concurrent combination;Heymach et al. 2007 荟萃分析:3918名患者;两者联用无优势的原因;化疗可能降低患者的EGFR基因突变发生率;Second, by a probably antagonistic effect between EGFR TKI and chemotherapy: EGFR TKI induces G1-phase cell cycle arrest that protects cancer cells from the lethal effect of cell cycle phase-dependent cytotoxic chemotherapy which arrest cells at the mitotic cell cycle phase. EGFR TKI使细胞停滞在G1期，而细胞周期依赖的化疗药物仅对M期的细胞起作用;EGFR-TKI + 化疗--耐药后的治疗选择;化疗 ± 特罗凯?治疗获得性耐药的患者;耐药后继续TKI同步化疗可能会成为有价值的治疗策略 尤其是对症状有进展的患者 能获得更高缓解率 ;实验二：;序贯联用Intercalated Combination;First-lin